A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain [Evaluación económica de la utilización de hierro carboximaltosa en pacientes con deficiencia de hierro e insuficiencia cardiaca crónica en España]
Comin-Colet J.,Programa de Insuficiencia Cardiaca |
Comin-Colet J.,Institute Investigaciones Medicas IMIM |
Comin-Colet J.,Autonomous University of Barcelona |
Rubio-Rodriguez D.,Health ValueMadrid |
And 7 more authors.
Revista Espanola de Cardiologia | Year: 2015
Introduction and objectives Treatment with ferric carboxymaltose improves symptoms, functional capacity, and quality of life in patients with chronic heart failure and iron deficiency. The aim of this study was to assess the cost-effectiveness of ferric carboxymaltose treatment vs no treatment in these patients. Methods We used an economic model based on the Spanish National Health System, with a time horizon of 24 weeks. Patient characteristics and ferric carboxymaltose effectiveness (quality-adjusted life years) were taken from the Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure trial. Health care resource use and unit costs were taken either from Spanish sources, or from the above mentioned trial. Results In the base case analysis, patients treated with and without ferric carboxymaltose treatment acquired 0.335 and 0.298 quality-adjusted life years, respectively, representing a gain of 0.037 quality-adjusted life years for each treated patient. The cost per patient was a €824.17 and €597.59, respectively, resulting in an additional cost of €226.58 for each treated patient. The cost of gaining 1 quality adjusted life year with ferric carboxymaltose was €6123.78. Sensitivity analyses confirmed the robustness of the model. The probability of ferric carboxymaltose being cost-effective (< €30 000 per quality-adjusted life year) and dominant (more effective and lower cost than no treatment) was 93.0% and 6.6%, respectively. Conclusions Treatment with ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, is cost-effective in Spain. Full English text available from: www.revespcardiol.org/en. © 2014 Sociedad Española de Cardiología. Source